Efficacy of BRAF‐Inhibitor Therapy in BRAF(V600E)‐Mutated Adult Langerhans Cell Histiocytosis

Langerhans cell histiocytosis (LCH) is a rare histiocytic neoplasm. To date, there is a lack of U.S. Food and Drug Administration–approved treatments in adult LCH to establish optimal first‐line therapy. We conducted a retrospective, single‐center case series evaluating the use of BRAF inhibitors in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Hazim, Antonious Z., Ruan, Gordon J., Ravindran, Aishwarya, Abeykoon, Jithma P., Scheckel, Caleb, Vassallo, Robert, Ryu, Jay H., Tobin, W. Oliver, Koster, Matthew J., Bennani, N. Nora, Rech, Karen L., Young, Jason R., Shah, Mithun V., Goyal, Gaurav, Go, Ronald S.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Commentary
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7938396/
https://ncbi.nlm.nih.gov/pubmed/32985015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13541
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados